Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma

• Published in: Cancer treatment and research communications Vol. 27; p. 100342
• Main Authors: Park, Robin, Al-Jumayli, Mohammed, Miller, Kirk, Saeed, Azhar, Saeed, Anwaar
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 2021; Elsevier
• Subjects: Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - analogs & derivatives; Camptothecin - pharmacology; Camptothecin - therapeutic use; Carcinoma, Pancreatic Ductal - diagnosis; Carcinoma, Pancreatic Ductal - drug therapy; Carcinoma, Pancreatic Ductal - genetics; Carcinoma, Pancreatic Ductal - pathology; Drug Resistance, Neoplasm - genetics; Epidermal growth factor receptor; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Erlotinib Hydrochloride - pharmacology; Erlotinib Hydrochloride - therapeutic use; Exon-19 mutation; Exons; Female; Fluorouracil - pharmacology; Fluorouracil - therapeutic use; Humans; Leucovorin - pharmacology; Leucovorin - therapeutic use; Middle Aged; Mutation; Neoplasm Staging; Pancreatic adenocarcinoma; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - pathology; Proto-Oncogene Proteins p21(ras) - genetics; Treatment Outcome; Exon-19 mutation; Pancreatic adenocarcinoma; Epidermal growth factor receptor
• ISSN: 2468-2942; 2468-2942
• DOI: 10.1016/j.ctarc.2021.100342

Advanced pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with an abysmal prognosis. Beyond the first-line setting, treatment for advanced PDAC is limited and suboptimal. Also, the efficacy of epidermal growth factor receptor (EGFR) targeted therapy alone in the chemo-refractory setting in PDAC tumors harboring druggable EGFR mutations is unclear. Here we describe the case of a patient with chemo-refractory advanced PDAC with an activating exon-19 EGFR mutation who had an exceptional response to erlotinib monotherapy.